BEIJING, April 19 (Xinhua) -- Berry Genomics, China's leading gene sequencing firm, reported a 45.7 percent growth in net profit attributable to shareholders of the listed company in 2019.
The company said its net profit hit 391 million yuan (55 million U.S. dollars) last year.
In 2019, its revenue reached 1.6 billion yuan, up 12.35 percent year on year.
Established in May 2010, Berry Genomics uses gene sequencing technology to mainly provide a "non-invasive" overall solution for clinical medical disease screening and diagnosis.
The Beijing-based company listed in August 2017 had the total assets worth 3 billion yuan by the end of 2019, up 40.9 percent year on year. Enditem
A single purchase
